Q&A: How pharma partnerships could benefit digital therapeutics companies

Austin Speier, chief strategy officer at Click Therapeutics, discusses the company's expanded partnership with Boehringer Ingelheim. The development of prescription digital medicines for people with schizophrenia was the focus of an announcement made by Click Therapeutics towards the end of 2022 that it was expanding its relationship with Boehringer Ingelheim. For digital health businesses including Click, which has a number of products in development, pharma relationships are nothing new. Austin Speier, the company's chief strategy officer, stated that Click seeks to partner with pharmaceutical firms that see carefully crafted digital medicines as possible treatments on par with medications. In an interview with MobiHealthNews, Speier talked about the extended relationship and the potential benefits of pharmaceutical alliances for companies developing digital therapies. MobiHealthNews: The expansion of your collaboration with Boehringer Ingelheim was just announced.